The most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Obinutuzumab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Obinutuzumab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Obinutuzumab. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Obinutuzumab. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Obinutuzumab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Obinutuzumab. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Obinutuzumab. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Obinutuzumab. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Obinutuzumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Obinutuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Obinutuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obinutuzumab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Obinutuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Obinutuzumab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Obinutuzumab. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Obinutuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Obinutuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Obinutuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Obinutuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obinutuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Obinutuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obinutuzumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Obinutuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Obinutuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obinutuzumab. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Obinutuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Obinutuzumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Obinutuzumab. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Obinutuzumab. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Obinutuzumab. |
| Cladribine | Obinutuzumab may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Obinutuzumab. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Obinutuzumab. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Obinutuzumab. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Obinutuzumab. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Obinutuzumab. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Obinutuzumab. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Obinutuzumab. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Obinutuzumab. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Obinutuzumab. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Obinutuzumab. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Obinutuzumab. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Obinutuzumab. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Obinutuzumab. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Obinutuzumab. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Obinutuzumab. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Obinutuzumab. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Obinutuzumab. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Obinutuzumab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Obinutuzumab. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Obinutuzumab. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Obinutuzumab. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Obinutuzumab. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Obinutuzumab. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Obinutuzumab. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Obinutuzumab. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Obinutuzumab. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Obinutuzumab. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Obinutuzumab. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Obinutuzumab. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Obinutuzumab. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Obinutuzumab. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Obinutuzumab. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Obinutuzumab. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Obinutuzumab. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Obinutuzumab. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Obinutuzumab. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Obinutuzumab. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Obinutuzumab. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Obinutuzumab. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Obinutuzumab. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Obinutuzumab. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Obinutuzumab. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Obinutuzumab. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Obinutuzumab. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Obinutuzumab. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Obinutuzumab. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Obinutuzumab. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Obinutuzumab. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Obinutuzumab. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Obinutuzumab. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Obinutuzumab. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Obinutuzumab. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Obinutuzumab. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Obinutuzumab. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Obinutuzumab. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Obinutuzumab. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Obinutuzumab. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Obinutuzumab. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Obinutuzumab. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Obinutuzumab. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Obinutuzumab. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Obinutuzumab. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Obinutuzumab. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Obinutuzumab. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Obinutuzumab. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Obinutuzumab. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Obinutuzumab. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Obinutuzumab. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Obinutuzumab. |